Correction to “Trametinib Overcomes KRAS ‐G12V–Induced Osimertinib Resistance in a Leptomeningeal Carcinomatosis Model of EGFR ‐Mutant Lung Cancer”
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsLung Cancer Treatments and Mutations · Brain Metastases and Treatment · Lung Cancer Research Studies
K. Fukuda, S. Otani, S. Takeuchi, et al., “Trametinib Overcomes KRAS‐G12V–Induced Osimertinib Resistance in a Leptomeningeal Carcinomatosis Model of EGFR‐Mutant Lung Cancer,” Cancer Science 112 (2021): 3784–3795. https://doi.org/10.1111/cas.15035.
In the above article, Figure 6B is incorrect. In Figure 6B, the image for “Control, Day 7” was inadvertently duplicated from “Osimertinib, Day 7” during figure assembly. The corrected panel is shown below. The color scale and radiance range are identical to the published figure (1 × 10^6^ – 2 × 10^8^ p/sec/cm^2^/sr). This error is limited to the representative image and does not affect the quantitative data in Figure 6A, the text, or the conclusions of the article. We apologize for the oversight.
The correct image is shown below:
We apologize for this error.